Omicia Inc, Oakland, Calif, has acquired Spiral Genetics, Seattle. Spiral’s advanced tools add multiple variant detection capabilities for next-generation sequencing (NGS) to Omicia’s software platform.
Spiral’s graph-based technology enables accurate detection of structural variants and provides population-scale data-mining capabilities for clinical laboratories, life science companies, and regional sequencing programs. Also included in the acquisition are Spiral’s population-specific reference genome and lossless data compression technologies. The acquisition will provide Omicia and its customers with new opportunities to develop novel diagnostics and efficiently manage long-term genomic data storage.
Adina Mangubat, Spiral Genetics.
“We’re excited to combine our team and technology with Omicia,” says Adina Mangubat, CEO of Spiral Genetics. “Access to Omicia’s diverse customer base, global market position, and market-leading platform will help us define the future of healthcare.”
Omicia now offers a secure, powerful range of NGS analysis capabilities to support high- throughput panels, exomes, and whole genomes for identification of hereditary diseases and somatic cancer, delivering clinical reports straight into electronic medical record workflows.
Matt Tindall, Omicia.
“The strategic integration of Spiral’s technologies effectively cements Omicia’s leadership position in precision medicine,” says Matt Tindall, CEO of Omicia. “By removing the need to access multiple software platforms, we improve quality, accuracy, and turnaround time, removing major roadblocks to clinical adoption.”
For more information, visit Omicia.
